<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845257</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol DG3.0 - 25.06.2018</org_study_id>
    <nct_id>NCT03845257</nct_id>
  </id_info>
  <brief_title>Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma</brief_title>
  <official_title>Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scientific research focuses on &quot;eosinophilic inflammation&quot; as it seems to guide the
      therapeutic regimen in patients with asthma and COPD. The primary objective of this
      prospective trial is to evaluate which parameter(s) best reflects eosinophilic inflammation
      by correlating tissue eosinophils (endobronchial biopsy, protected specimen brush sampling)
      with FeNO, peripheral blood eosinophils, and eosinophils in the bronchoalveolar lavage of
      patients with obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective trial. Enrollment will continue until 150 patients with
      chronic obstructive pulmonary disease and 50 patients with severe asthma have been entered
      into this trial and have completed bronchoscopic evaluation. In this trial, the following
      parameters are to be evaluated:

        -  Blood eosinophils (absolute and relative)

        -  FeNO

        -  Eosinophils in bronchoalveolar lavage

        -  Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 14, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of eosinophilic inflammation by correlating tissue eosinophilia with eosinophil count in blood/BAL and FeNO measurement.</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation of FeNO, blood eosinophils, bronchoalveolar lavage findings and bronchial epithelium histopathology in patients with chronic obstructive pulmonary disease and asthma</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Obstructive Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Patients with COPD</arm_group_label>
    <description>The following parameters are to be evaluated:
Blood eosinophils
FeNO
Eosinophils in bronchoalveolar lavage
Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with asthma</arm_group_label>
    <description>The following parameters are to be evaluated:
Blood eosinophils
FeNO
Eosinophils in bronchoalveolar lavage
Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling</intervention_name>
    <description>Blood sampling (eosinophil count; eosinophilia is defined as &gt;300/µl (or &gt;150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.</description>
    <arm_group_label>Patients with COPD</arm_group_label>
    <arm_group_label>Patients with asthma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of COPD or asthma (according to the guidelines)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of COPD or asthma (according to the guidelines)

          -  Age &gt;18 years

          -  Indication for bronchoscopy for medical reasons (not study-related)

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  paO2 &lt;60 mmHg on 4L 02 /min, paCO2 &gt; 55 mmHg on room air

          -  FEV1 &lt;20%

          -  Pulmonary infection or exacerbation within the last 4 weeks

          -  Additional pulmonary diseases (pneumonia, lung cancer, tuberculosis, interstitial lung
             disease)

          -  Contraindication for BAL, PSB sampling or endobronchial biopsy

          -  Current use of anticoagulants that can not be stopped for bronchoscopy

          -  Heart failure with left ventricular ejection fraction &lt;30%

          -  Myocardial infarction in previous 6 months

          -  Significant pulmonary hypertension (PAPS &gt;45 mmHg, right heart failure
             [echocardiography] and/or PAPm &gt;35 mmHg [right heart catheter])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Gompelmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik University Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Gompelmann</last_name>
    <phone>004962213968087</phone>
    <email>daniela.gompelmann@directbox.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Macquarie University Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alvin Ing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Clinical Infectious Diseases/Research Center Borstel</name>
      <address>
        <city>Borstel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Heyckendorf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik University Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Gompelmann</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Daniela Gompelmann</investigator_full_name>
    <investigator_title>Daniela Gompelmann, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

